Dept. of Pharmacology and Toxicology, Virginia Commonwealth Univ., Richmond, 23298, USA.
Am J Physiol Cell Physiol. 2010 May;298(5):C1209-16. doi: 10.1152/ajpcell.00533.2009. Epub 2010 Mar 3.
Activation of the death receptor Fas has been implicated in the development of vascular injury or disease, but most studies have focused on its role in the regulation of cell apoptosis and growth. The present study was designed to examine the early response of coronary artery to Fas activation by its ligand, FasL. The hypothesis being tested is that CD38 signaling pathway mediates FasL-induced intracellular Ca(2+) release through nicotinic acid adenine dinucleotide phosphate (NAADP) in mouse coronary arterial myocytes (CAMs) and thereby produces vasoconstriction in coronary arteries. HPLC analysis demonstrated that FasL markedly increased NAADP production in CAMs from wild-type mice (CD38(+/+)) but not in cells from CD38 knockout (CD38(-/-)) mice. Using fluorescent Ca(2+) imaging analysis, we found that FasL (10 ng/ml) significantly increased Ca(2+) release from 142.5 +/- 22.5 nM at the basal level to 509.4 +/- 64.3 nM in CD38(+/+) CAMs but not in CD38(-/-) CAMs. However, direct delivery of NAADP, the CD38 metabolite, into CD38(-/-) CAMs still markedly increased Ca(2+) release, which could be significantly attenuated by a lysosomal function inhibitor, bafilomycin A1 (Baf), or a NAADP antagonist, pyridoxalphosphate-6-azophenyl-2-disulfonic acid. Confocal microscopy further demonstrated that FasL produced a typical two-phase Ca(2+) release with a local Ca(2+) burst from lysosomes, followed by a global Ca(2+) response in CD38(+/+) CAMs. In isolated perfused septal coronary arteries from CD38(+/+) mice, FasL was found to significantly increase U-46619-induced vasoconstriction from 29.2 +/- 7.3 to 63.2 +/- 10.3%, which was abolished by Baf (100 nM). These results strongly indicate that the early response of CAMs to FasL is to increase intracellular Ca(2+) levels and enhance the vascular reactivity through stimulation of NAADP production and lysosome-associated two-phase Ca(2+) release in coronary arteries.
Fas 死亡受体的激活被认为与血管损伤或疾病的发生有关,但大多数研究都集中在其对细胞凋亡和生长的调节作用上。本研究旨在观察 Fas 配体 FasL 激活对冠状动脉的早期反应。正在测试的假设是,CD38 信号通路通过烟酰胺腺嘌呤二核苷酸磷酸(NAADP)介导 FasL 诱导的细胞内 Ca2+释放,从而在冠状动脉中产生血管收缩。HPLC 分析表明,FasL 可显著增加野生型小鼠(CD38(+/+))冠状动脉心肌细胞(CAM)中的 NAADP 产生,但不能增加 CD38 敲除(CD38(-/-))小鼠细胞中的 NAADP 产生。使用荧光 Ca2+成像分析,我们发现 FasL(10ng/ml)可使 CD38(+/+) CAM 中的 Ca2+释放从基础水平的 142.5±22.5 nM 显著增加至 509.4±64.3 nM,但在 CD38(-/-) CAM 中无此作用。然而,直接将 CD38 代谢物 NAADP 递送至 CD38(-/-)CAM 中仍可显著增加 Ca2+释放,该作用可被溶酶体功能抑制剂巴弗洛霉素 A1(Baf)或 NAADP 拮抗剂吡哆醛 6-偶氮苯-2-二磺酸显著抑制。共聚焦显微镜进一步表明,FasL 可在 CD38(+/+)CAM 中产生典型的两阶段 Ca2+释放,从溶酶体中产生局部 Ca2+爆发,随后发生全局 Ca2+反应。在来自 CD38(+/+)小鼠的分离灌注的隔冠状动脉中,发现 FasL 可显著增加 U-46619 引起的血管收缩,从 29.2±7.3%增加至 63.2±10.3%,而 Baf(100nM)可消除此作用。这些结果强烈表明,CAM 对 FasL 的早期反应是通过刺激冠状动脉中 NAADP 产生和溶酶体相关的两阶段 Ca2+释放来增加细胞内 Ca2+水平并增强血管反应性。